1.
Ann Hematol
; 91(4): 637-8, 2012 Apr.
Article
in English
| MEDLINE
| ID: mdl-21833478
Subject(s)
Myeloproliferative Disorders/genetics , Proto-Oncogene Proteins c-ets/genetics , Receptor, Platelet-Derived Growth Factor beta/genetics , Recombinant Fusion Proteins/genetics , Repressor Proteins/genetics , Antineoplastic Agents/therapeutic use , Benzamides , Female , Humans , Imatinib Mesylate , Middle Aged , Myeloproliferative Disorders/drug therapy , Piperazines/therapeutic use , Proto-Oncogene Proteins c-ets/metabolism , Pyrimidines/therapeutic use , Receptor, Platelet-Derived Growth Factor beta/metabolism , Recombinant Fusion Proteins/metabolism , Repressor Proteins/metabolism , ETS Translocation Variant 6 Protein
2.
J Gastrointest Cancer
; 43 Suppl 1: S84-8, 2012 Sep.
Article
in English
| MEDLINE
| ID: mdl-22038668
Subject(s)
Adenocarcinoma/pathology , Esophageal Neoplasms/pathology , Meningeal Carcinomatosis/secondary , Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols , Esophageal Neoplasms/drug therapy , Humans , Male , Meningeal Carcinomatosis/drug therapy , Middle Aged , Prognosis , Tomography, X-Ray Computed
3.
Clin Breast Cancer
; 11(5): 342-5, 2011 Oct.
Article
in English
| MEDLINE
| ID: mdl-21729664
ABSTRACT
Primary neuroendocrine carcinoma (PNEC) of the breast is extremely rare.(1) Because of the rarity of this cancer, long-term prognosis, biologic behavior, and treatment are not well known. PNEC can have high expression of estrogen receptor (ER) and progesterone receptor (PR). It is important to differentiate PNEC of the breast from other metastatic diseases to the breast because of the differences in treatment. We herein report the successful treatment of a patient with PNEC of the breast and high expression of ER and PR by means of hormonal therapy.
